Samer Al Hadidi, MD,MS,FACP @HadidiSamer Twitter profile | Pikagi

Pikagi

Samer Al Hadidi, MD,MS,FACP

@HadidiSamer

4,489

Followers

312

Following

2,521

Media

5,954

Statuses

Assistant professor @UAMSMyeloma . Alumni heme/onc @bcmhouston , clinical research/biostat @UMich .Focus on plasma cell disorders & health disparities

Little Rock, AR

https://t.co/iBmqjbVcZJ

Joined August 2012

Don't wanna be here? Send us removal request.

Pinned Tweet

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

Myeloma is a curable malignancy #mmsm Yes it is curable The cure rate is not ideal (not all/most patients are cured)- there is still work to be done to improve We estimate that one out of three patients with standard risk myeloma (vast majority of cases) are cured 🧵

Tweet media one

4

21

126

Last Seen Profiles

@AlphaTylerD

@avstempel

@arnoldmanzi00_

@DanielVanThomas

@natanordnata

@maru_acpc

@1OutlawBandit

@CoachJCorms

@Grimware_Games

@soyleonC

@shiny_tia_

@chenlecowayo

@DommyBelle

@No_oNe571

@Explicit_Majay

@TLHumanRights

@divagarant

@svspel_esport

@doaenel

@haru_rk7979

@EllieValin87183

@pevchikh

@noghty_sami

@EPraeteritum

@CJhansford2026

@SAnetsberg71398

@CybermercCom

@fulya741

@slowlor1s

@LLE_97

@CathAdams1973

@PinkMarked

@sonofhajia45

@willmofield

@Ruffy1991258595

@Cr3470

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

#MedTwitter Hungry macrophage👇(can see in macrophage activation syndromes/HLH/Infections/etc) It already ate: ➡️red cells ➡️platelets ➡️monocytes ➡️neutrophils ➡️lymphocyte ⭐️The result is pancytopenia

Tweet media one

6

76

301

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Little Rock, Arkansas just got hit by a major tornado. Many people lost their homes and damage is still to be estimated We are safe and blessed, thank you for all who reached out Please keep all people here in your thoughts and prayers

18

50

186

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#MedTwitter 🩸Nurse cell in bone marrow ⭐️macrophage surrounded by erythroblasts to supply iron & nutrition to these cells for formation of RBCs

Tweet media one

5

30

163

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#MedTwitter #AcademicTwitter observation on authorship and number of patients enrolled per author/country🧵 Will use this recent paper as example 👇 Assigning authorship maybe a complex process and depend on many other variables but it is interesting to notice the following:

Tweet media one

8

28

155

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

A personal story about struggles I encountered during my first year of fellowship as I coped with the loss of my father. #ASCOconnection @ASCO ➡️

Tweet card media

Dr. Samer Al Hadidi shares a personal story about the struggles he encountered during his first year of fellowship as he coped with the loss of his father.

connection.asco.org

21

12

121

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

It is an honor to win the @GoHealio Health Equity Disruptive Innovator Award for 2023 @ASCO #ASCO23 #mmsm #MedTwitter Such a privilege to be recognized, thank you for the nomination and the award. It is a true honor The goal is equitable healthcare for all

Tweet media one

Tweet media two

Tweet media three

27

10

122

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Check out our new paper published @BloodAdvances @ASH_hematology and led by our @UAMSintmedicine @FarahMazahreh presented #ASH22 Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis #mmsm ➡️ 🧵

Tweet media one

8

32

119

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

11 months

Grateful for the @Myeloma_Society for receiving young investigator award #mmsm #IMS23 on the work of secondary malignancies in long term transplant patients

Tweet media one

23

9

114

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm How do I treat smoldering myeloma? Observation How do I treat “high risk” smoldering myeloma? Observation Why don’t I enroll on most clinical trials of smoldering myeloma? Because they assume that treatment (active control arm) is beneficial 🧵

8

30

112

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

#mmsm Despite the fact that Elranatamab data seem to be better than Teclistimab data, both were single-arm studies that cannot be compared. I made a summary 👇 We need less frequent/finite dosing in a trial setting (Elran had less dosing in a trial setting not per investigator👇)

Tweet media one

7

21

110

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 month

This is an updated results data of BCMA CAR-T and BCMA BsAb with updated data from recent presentations/publications based on few requests I got #mmsm ✅Updated data for Elranatamab looks great ✅In areas with equal access to CAR-T: no role for ide cel ✅Excellent BsAb data

Tweet media one

6

24

109

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme boards- slide from @ASH_hematology board review series summarizing 4 platelet disorders that usually appear in boards 👇👇

Tweet media one

0

19

99

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Blood smears @ASH_hematology 🧵Heme boards 🩸Malignant Hematopoietic Neoplasms🩸 #mmsm #lymsm #leusm #bmtsm 1⃣ classic Hodgkin's lymphoma 🩸Reed-Sternberg cell👇 🩸Most common: Nodular sclerosis 👇(fibrosis) 🩸Usually:CD30+, CD15+, weak PAX5 +. CD20-, CD45- 🩸9p24.1 alteration

Tweet media one

Tweet media two

7

30

96

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

How I Treat AL Amyloidosis @BloodJournal | @ASH_hematology #MMsm ➡️ Nice practical review,summary tables&suggested treatment algorithms with 5 cases ➡️Link: 🛑 it is amazing how science is advancing.Doxycycline study mentioned👇 just reported as negative

Tweet media one

Tweet media two

Tweet media three

Tweet media four

2

39

90

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

#mmsm Pleased to announce that I will be presenting an oral presentation @Myeloma_Society #IMS23 @UAMSMyeloma @uamscancer and I will receive IMS young investigator award for exemplary abstract Our group will present 2 oral abstracts, looking forward for a productive meeting

Tweet media one

19

3

88

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Summary of erythrocytes inclusion bodies: 1️⃣Howell-Jolly body ➡️composition: DNA 🔬associations: splenectomy, hyposplenism, megaloblastic anemia, hemolytic anemia, sickle cell disease #MedTwitter @ASH_hematology @BCMDeptMedicine

Tweet media one

4

43

81

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

#ASCO24 #mmsm The rapid plenary is now published @NEJM @ASCO Initial thoughts

Tweet media one

1

20

80

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme board-Splenic MZL ⭐️Splenomegaly(>80%) ➡️ Smear:villous lymphocytes (~1/3)👇 ➡️Association:hepatitis C(up to 20%) ~ HCV+: anti-HCV ~ HCV- (or failed anti-HCV):observation until ttt indication, rituximab(R), or R+bendamustine ~ Relapsed after R:Ibrutinib(ORR~60%) #medtwitter

Tweet media one

1

18

84

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

#ASH21 How to access the "educational book" online chapters? @ASH_hematology 1⃣Go to program➡️sessions 2⃣Use filter:education and days 3⃣You will have a list,choose one 4⃣Scroll down until you see same name of presentation in red (small box) 5⃣See recording&PDF link(circle)

Tweet media one

Tweet media two

Tweet media three

Tweet media four

1

23

83

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm #MedTwitter @BloodJournal @ASH_hematology A practical guide, very helpful read 👇 How I manage infection risk and prevention in patients with lymphoid cancer

Tweet media one

Tweet media two

Tweet media three

Tweet media four

1

36

82

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Unfortunately high publication fees affect academia negatively Only researchers/institutions/Pharma who can pay such high amounts can publish. Trainees, researchers with no financial support suffer more. @inas_md & me wrote: #AcademicTwitter

Tweet card media

The Inflation in Oncology Publications and Journals: A Vicious Cycle That Needs Immediate Attention

Published in Cancer Investigation (Vol. 41, No. 3, 2023)

www.tandfonline.com

@AaronGoodman33

Aaron Goodman - “Papa Heme”

@AaronGoodman33

1 year

Wow Blood Cancer Journal charges 4790 bucks to publish? I like some of the articles in this journal but had no idea. Why would anyone pay this?

Tweet media one

18

9

88

5

11

76

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme board review, slide from @ASH_hematology board review series summarizing 4 platelet disorders that usually appear in bords 👇👇

Tweet media one

1

14

80

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

4 years

Published at @NEJM . VIALE-A trial. Combination of AZA and Venetoclax resulted in ~5 months improvement in OS in elderly patients ineligible for intensive chemotherapy. Dr DiNardo et al @LeukemiaMDA

Tweet media one

4

27

77

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management @MorieGertz @AjHematology ✅ An excellent UpToDate review of WM 👇 #mmsm #OncTwitter ➡️

Tweet media one

3

37

74

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

🩸Heme boards🩸CAR-T made easy🧵 ➡️Approved products/indications 1⃣Tisagenlecleucel (Kymriah): Refractory/Relapsed(>=2L) B-ALL (up to age 25yrs) & R/R Large B cell lymphoma(>=2L) 2⃣ Axicabtagene Ciloleucel (Yescarta):R/R Large B cell lymphoma(>=2L)& R/R follicular lymphoma(>=2L)

2

27

74

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Check our new paper: Visa Constraints and Career Choices for Oncologists @JNCCN @FarahMazahreh @ahmadalhader #MedTwitter #OncoTwitter #AcademicTwitter Thankful for Journal of the National Comprehensive Cancer Network for allowing us to publish this🧵 ➡️

Tweet media one

Tweet media two

Tweet media three

4

24

72

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

An excellent review article @NEJM on autoimmune hemolytic anemia ➡️ Link: ➡️ 3 figures/tables to summarise the topic 👇 ➡️ High yield for heme boards 🩸 #MedTwitter #hematology

Tweet media one

Tweet media two

Tweet media three

0

22

73

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Why peripheral neuropathy incidence is lower and cardiac toxicity is higher with carfilzomib when compared to bortezomib in multiple myeloma? #mmsm 🧵

Tweet media one

3

16

70

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Check out our #ASH22 abstract #mmsm Clinical Outcome of pts with Relapsed Refractory MM Listed for BCMA Directed Commercial CAR T ➡️ 🛑Cumulative incidence of receiving CAR-T at 12 mo from listing:29% LOW 🛑About a third of pts died waiting for CAR-T

Tweet media one

2

22

70

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme-Onc boards- ALL prognosis 🛑Bad 🪧older age 🪧Ph chrom t(9;22) 🪧MLL translocation(KMT2A) 🪧t(8;14) 🪧Complex karyotype(>=5 abnormalities) 🪧Low hypodiploid (30-39 chrom,associated with TP53) 🪧“Ph-like”,CRLF2 alterations 🪧IKZF1 🪧TP53 🪧Early T-cell phenotype

1

15

68

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

Check our paper Characteristics of Post-hoc Subgroup Analyses of Oncology Clinical Trials: A Systematic Review #mmsm #OncTwitter ➡️ Led by a great team of students in 🇯🇴: Jawad, Marah, Muntaser, Nada and Yazan Relevant as we approach #ASH23 🧵

Tweet media one

2

14

69

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

One of the most important resources for @HemOncFellows #ASH23 #mmsm is the ASH Educational book @ASH_hematology #OncTwitter All articles are here:

Tweet media one

1

16

67

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Hematology boards- AML DO&DON’T 🛑DON’T ➡️transplant ELN favorable risk patients in CR1:Inv(16)(core binding factor),t(8;21),NPM1 w/o FLT3-ITD,or dmCEBPA(biallelic,dual mutant) ⭐️DO ➡️know ELN risk stratification👇 ➡️decrease dose of venetoclax when using posa/vori-conazole

Tweet media one

1

12

66

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

6 months

#mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta cel and Ide cel, assuming having access to both for a given patient, I will personally chose Cilta cel (I explained this before) 🧵

5

26

66

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 months

Nicely written review on systematic AL amyloidosis #mmsm highly recommended @NEJM @vsanchorawala Multiple nice figures and tables, some👇

Tweet media one

Tweet media two

Tweet media three

Tweet media four

0

17

66

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm Our first issue of the @japacademy journal is out. Check out my short paper on primary plasma cell leukaemia 👇 Lots of efforts in this project 🇯🇴🇺🇸, articles covering wide variety of medical sub-specialities

Tweet media one

3

13

65

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Here I provide screen shots of important slides (IMO) presented @ASH_hematology ➡️ASH Hematology Board Review series. Excellent resource,great presenters and tremendous efforts #ASHTrainee 👏👏 🧵review those slides prior to the exam🧵 #MedTwitter @HemOncFellows Benign heme 1/2

1

11

65

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#ASH22 @ASH_hematology Zanubrutinib vs. Ibrutinib (R/R CLL/SLL): ALPINE Phase 3 Study Interesting! zanubrutinib has now proven superiority to ibrutinib in both ORR and PFS in pts with R/R CLL/SLL

Tweet media one

6

18

64

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Check out our new paper @BloodAdvances @ASH_hematology : Gender and Early-career Faculty Disparities in Hematology and Oncology Board Review Lecture Series #MedTwitter #OncTwitter ➡️Link: 🧵👇

Tweet media one

4

17

63

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Important paper @iStopMM #mmsm @NatureMedicine @SigrunThorstei1 @sykristinsson Prevalence of smoldering multiple myeloma based on nationwide screening ➡️ Congratulations for all authors for publication , few thoughts/observations 🧵

Tweet media one

3

22

62

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm First randomized trial investigating ide-cel in myeloma published in @NEJM today Few important observations 🧵

Tweet media one

1

11

59

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 months

A thread about academic moderation #MedTwitter While many may not realize this but there is ongoing fear/avoidance from new graduates to join academia in the field of hematology and medical oncology due to excessive trespassing of personal/family time We can/should do better 🧵

3

12

60

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Dinner with Bart Barlogie while discussing myeloma history and advances, academia, cure and life. Lots of wisdom Stay tuned for some good future things to come #mmsm

Tweet media one

2

3

59

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

4 years

I just got my COVID-19 vaccine for my own health, my family health and for my patients. Thank you Baylor College of Medicine. Let’s end this pandemic together. #WearAMask #StickItToCOVID . #BCMCares @bcmhouston @BCMHemeOnc @BCMCancerCenter @harrishealth #oncology #CoronaVaccine

Tweet media one

Tweet media two

0

3

60

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme/Onc boards-Chronic neutrophilic leukemia ⭐️Diagnosis 🪧WBCs ≥25,>80% segs/bands & <10% immature precursor cells,smear👇 🪧Hypercellular marrow,<5% myeloblasts 🪧Normal neutrophil maturation, granulocytic dysplasia 🪧No reactive causes of neutrophilia 🩸mutation: CSF3R

Tweet media one

2

16

60

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm Check out our recent review paper on venous thrombosis prophylaxis in multiple myeloma @UAMSMyeloma @uamshealth @uamscancer 🧵 with important summaries

Tweet media one

5

21

56

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

7 months

Check our @UAMSMyeloma new paper @NatureComms @Nature Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth #mmsm ➡️ BCMA-CD24-CAR-T can effectively target bulk MM tumor cells&reduce numbers of minimal residual MM cells&modulate microenvironment

Tweet media one

Tweet media two

2

11

55

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 month

Dara-RVd now approved by @FDAOncology for newly diagnosed myeloma patients who are transplant eligible #mmsm ➡️

Tweet card media

FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenal

On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) in combination with bortezomib, lenalidomide, and...

3

15

56

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Oncology boards- GIST Mutation/ttt 🪧Exon 9/Imatinib 800mg 🪧Exon 11/Imatinib 400mg 🪧Exon 17/Regorafenib 🪧PDGFRA exon 18D842V/Avapritinib

1

14

54

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

8 months

Check the Winter 2023 Myeloma Magazine @UAMSMyeloma @uamscancer @uamshealth #mmsm ➡️ 🧵

Tweet media one

1

4

54

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

Just at the right time #ASH23 Check our recent paper @jcan_policy #mmsm Use of Subjective Minimizing Language at Hematology and Oncology Conferences: A Systematic Review ➡️ When you read abstracts and go to presentation watch out for this phenomena 🧵

Tweet media one

1

8

54

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Check out our work published today @JAMANetworkOpen : Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma #mmsm #disparities Published while in #IMS2022

Tweet media one

3

18

53

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Got my copy of Hematology where I contributed to a chapter on marginal zone lymphoma before my interest differentiated into plasma cells #mmsm , a great resource to add to my library before disappearance of books in the near future

Tweet media one

Tweet media two

Tweet media three

Tweet media four

2

1

53

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

#mmsm ⭐️Plasmablasts ➡️ immature plasma cells:basophilic cytoplasm,faint/absent perinuclear hof,large nucleus,diffuse chromatin, prominent nucleolus👇 ➡️Plasmablastic myeloma:MM+bone marrow infiltration ≥ 2% plasmablasts=more aggressive/worse prognosis #MedTwitter

Tweet media one

0

22

54

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

My top 7 #ASCO24 abstracts to watch for #mmsm Will have more details on those once presented/published- those are initial thoughts that may evolve according to more data There are more interesting data will highlight during the meeting @ASCO 🧵

4

10

53

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

#ASH23 #mmsm LBA PERSEUS study Dara-RVD vs RVD transplant eligible pts Notice relatively only 1 out of 5 are high risk pts Age is young at 59-61 (median) 1 out of 4 pts >65 yrs

Tweet media one

Tweet media two

Tweet media three

Tweet media four

3

14

52

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies @MolTherapy #mmsm #celltherapy #bmtsm #lymsm #leusm @UAMSMyeloma @CAGTHouston ➡️ Many figures and tables , check few 👇

Tweet media one

Tweet media two

Tweet media three

Tweet media four

1

18

52

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Help us spread the word&complete a survey to understand adoption of ICC/WHO myeloid&lymphoid neoplasm classification in 🇺🇸 ➡️can complete on your phone ✅project led by a fellow (👏) ➡️ #OncTwitter #HemeTwitter #AcademicTwitter #PathTwitter #hemepath

Tweet media one

4

37

47

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

22 days

Check our recent paper @UAMSMyeloma @AjHematology #mmsm : Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma ➡️ ✅n=1379 ✅Median FU:16.6 yrs ✅SHM:5.6% (1 vs 2 transplants=no difference)

Tweet media one

Tweet media two

1

15

51

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

#mmsm #ASCO24 Some nice summary slides from educational programs BsAbs vs. CAR-T therapy

Tweet media one

3

9

51

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

7 months

GMMG-HD6: Elotuzumab-RVD vs. RVD in newly diagnosed MM #mmsm @TheLancetHaem @EliasKarlMai Elotuzumab resulted in no benefit👇 ➡️ IMO, Elotuzumab has no role in myeloma, even in relapsed refractory disease. Congrats for authors publishing -ve study

Tweet media one

9

18

49

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Congratulations for all who submitted abstracts @ASCO annual meeting ⭐️Celebrate your hard work regardless of the results ⭐️If it does not work this time, it will work in the future ⭐️Take it to the next level and get your work published (be a finisher) #MedTwitter @HemOncFellows

Tweet media one

2

5

49

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 months

Check our recent paper: Weight loss and dysgeusia in relapsed/refractory MM patients treated with talquetamab #mmsm ➡️ ✅Dysgeusia persisted in 15% of pts ✅pts lost 6% of their weight during ttt, weight loss persisted in~half of pts post-discontinuation

Tweet media one

Tweet media two

2

14

49

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#ASH22 I am happy that many medical students,residents&fellows I mentored (and myself) will be able to present at @ASH_hematology @UAMSMyeloma @uamscancer #mmsm #MedTwitter #academia Our group will present posters &oral on very important topics,stay tuned for some good stuff

Tweet media one

2

3

47

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme boards-associations with extranodal MZL 🦠Bacteria ➡️H.Pylori:stomach ➡️Campylobacter jejuni:intestine(IPSID) ➡️Chlamydia psittaci:conjunctiva ➡️Borrelia burgdoferi:skin ➡️Achromobacter xylosoxidans:lung 🩸autoimmune ➡️Hashimoto:thyroid ➡️Sjögren:salivary/lacrimal gland

3

12

48

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Malignant heme-TKI in CML ⭐️ AEs 💊imatinib:edema,cramps,fatigue,GI 💊dasatinib:pleural/pericardial effusion 💊nilotinib:QT prolongation, hyperglycemia,vascular events(VE), pancreatitis 💊bosutinib:diarrhea,transaminitis 💊ponatinib:VE,heart failure,hepatotoxity,HTN,pancreatitis

1

11

48

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Vacation , time for Jordan, family and some good food 🇯🇴

Tweet media one

2

0

48

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

#mmsm #ASCO24 BENEFIT study Isa-VRd vs. Isa-Rd in transplant in-eligible pts Here velcade was dosed once weekly 🧵

Tweet media one

2

12

47

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

7 months

A very good review article about osteoporosis, relevant in patients with myeloma #mmsm @AnnalsofIM Osteoporosis | Annals of Internal Medicine ➡️ A Nice summary table of pharmacological intervention 👇

Tweet media one

0

19

45

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm Treating smoldering multiple myeloma (asymptomatic disease) with CAR-T therapy using any commercially approved product while pts with advanced/refractory multiple myeloma die waiting for CAR-T slot is unethical and should not be celebrated. Pts deserve better.

4

6

47

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme/onc boards-extravasation management 🪧Topical heat (VETO) ⭐️Vinca alkaloids (vinblastine,vincristine,vinorelbine) ⭐️Etoposide ⭐️Taxanes (docetaxel,paclitaxel) ⭐️Oxaliplatin 🪧Topical cold ⭐️others

3

9

46

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Myeloma is a field where we argue MM pts(actual cancer) don't require auto transplant while at same time we treat smoldering MM (an asymptomatic disease-may never progress to cancer) with a triplet regimen&auto transplant Make this make sense #mmsm #ASH22

4

8

46

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

#ASCO21 #mmsm Relapsed Multiple Myeloma: Does One Size Fit All? @ninashah33 ➡️ Dr Nina Shah is a great speaker, highly recommended lecture ➡️ Developments are great, there are too many products, cost is a major issue ➡️Summary tables👇including differences between approaches

Tweet media one

Tweet media two

Tweet media three

Tweet media four

0

23

44

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

Check out our new paper published @e_JHaem #mmsm @UAMSMyeloma @uamscancer Variability of definition of high-risk multiple myeloma across phase III clinical trials ➡️ 🧵

Tweet media one

2

18

44

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Looking forward for #ASH21 @ASH_hematology and happy to announce that I have one submission accepted as oral presentation & another one as poster. Moreover I am honored to be part of the ASH Poster walk this year to highlight some of the excellent work #mmsm @UAMSMyeloma

Tweet media one

7

3

46

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

7 months

Editorial @FDAOncology @NEJM #mmsm ✅22 cases out of 27,000, 14 with data ✅T-cell lymphoma,T-cell large granular lymphocytosis,peripheral T-cell lymphoma,cutaneous T-cell lymphoma 🛑3 cases with genetic info,CAR transgene detected in malignant clone ➡️

Tweet media one

Tweet media two

0

15

45

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Blood smears @ASH_hematology 🧵Heme boards 🩸Malignant Hematopoietic Neoplasms🩸 #mmsm #lymsm #leusm #bmtsm 1⃣ classic Hodgkin's lymphoma 🩸Reed-Sternberg cell👇 🩸Most common: Nodular sclerosis 👇(fibrosis) 🩸Usually:CD30+, CD15+, weak PAX5 +. CD20-, CD45- 🩸9p24.1 alteration

Tweet media one

Tweet media two

3

15

44

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme/Onc boards- Ibrutinib 💊AEs: atrial fibrillation(commonly asked), diarrhea (usually self-limited),initial lymphocytosis (peak 1-2 mo, observe), bleeding diathesis, HTN, rash, arthralgias, cytopenias 🛑risk of 2ry malignancy 🪧need dose adjustment with hepatic impairment

2

10

43

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Check out my correspondence on OCEAN trial and the authors reply #mmsm @TheLancetHaem ➡️ 🧵

Tweet media one

Tweet media two

1

10

44

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 months

#mmsm #ASCO24 Educational talk on high risk /ultra high risk @myelomaMD Nice summary slide 👇 One problem we have is the varying definition of high risk we showed before

Tweet media one

0

12

45

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#MedTwitter #HemeBoards @HemOncFellows 🧵Summary of erythrocytes inclusion bodies: 1️⃣Howell-Jolly body ➡️composition: DNA 🔬associations: splenectomy, hyposplenism, megaloblastic anemia, hemolytic anemia, sickle cell disease

Tweet media one

3

10

45

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

At time of #ASH23 , check our paper of total therapy IIIB with more than 15 years follow up in multiple myeloma @UAMSMyeloma #mmsm @BloodAdvances @ASH_hematology ➡️ This will be one of many papers to come with long follow up data 🧵

Tweet media one

1

6

44

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Happy that our campaign @UAMSMyeloma @uamscancer was able to provide support with more than 17,000$ to patients and their families in Arkansas #mmsm @LLSusa

Tweet media one

0

4

42

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Check out our recent paper: Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies | @BloodAdvances | @ASH_hematology #mmsm #leusm ➡️Link: ➡️ Virtual abstract👇 ⭐️>50% didn’t collect QoL measures 🧵

Tweet media one

2

11

43

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Myeloma is a field where we argue MM ttt cost is too much while at same time we treat smoldering MM (an asymptomatic disease-may never progress to cancer) with ~1 million $ 2yr-regimen (only drug cost) in a single arm study measuring short term response Make this make sense #mmsm

1

4

42

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Looking forward for #ASH22 Will be moderating an oral session discussing plasma cell disorders&transplant abstracts&co-chairing a poster walk highlighting best abstracts focused on heme malig disparities with @warren_fingrut #mmsm #bmtsm @UAMSMyeloma @uamscancer @ASH_hematology

Tweet media one

0

3

42

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

👇This is a major issue in academia Junior faculty suffer targeting, marginalisation&attacks Role models lead by good examples not by no. of NEJM publications Delete this article&do not amplify intimidating articles targeting junior faculty Academia has enough problems

@ManniMD1

Manni Mohyuddin

2 years

This article broke my heart and reminded me of all the toxicity in academia. I never have condoned any harsh speech against anyone, but I do have reason to believe I am being referred to in this article. I will highlight some themes in this important 🧵

40

43

269

1

7

42

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

#ASH23 #mmsm KarMMa-3 updated analysis Despite improved PFS with earlier use of Ide-Cel, OS was not different Unfortunate we don't have a tail for PFS with Ide-cel and unfortunate that OS is not better (per ITT, many pts died before product) Will use of CAR-T earlier be better?

Tweet media one

Tweet media two

Tweet media three

Tweet media four

4

13

40

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

9 months

#ASH23 #mmsm Oral myeloma @RahulBanerjeeMD Decreasing the dose of Dex does not seem to affect outcomes negatively In clinic the lower the dose, the better to avoid AEs for patients and improve QoL IMO

Tweet media one

Tweet media two

4

16

42

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Check out our viewpoint: Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? via @JAMAOnc part of @JAMANetwork #mmsm ➡️ we think @NCCN guidelines in Myeloma need to be re-visited due to multiple shortcomings 🧵 #mmsm

Tweet media one

3

5

41

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#mmsm 1/2 Things that need to stop in myeloma field 🛑weekly/daily conferences by same speakers 🛑multiple oral presentations by senior faculty 🛑review articles written by medical writers&stamped by name/s of “KOL” 🛑a “KOL”lecturing on benefits of a drug he/she takes >50k/yr

5

6

41

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

It is nice to see everyone sharing their top choices of #ASCO21 top abstracts @ASCO ,but let’s all agree: ⭐️ Kudos for all trainees who submitted and/or will be presenting their work 👏👏 #ASCOtrainee ⭐️Constructive feedback is needed and we should all strive to provide it

Tweet media one

0

6

42

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Fellowship ✔️ completed A long road of medical school, residency, faculty job in Internal Medicine, school of public health/biostatistics and heme/onc fellowship is coming to the end ➡️ I am thankful for my family, friends, colleagues and mentors for support and guidance.

Tweet media one

4

0

41

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

1 year

The final version of our publication: Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis #mmsm @BloodAdvances @ASH_hematology @UAMSMyeloma ➡️

Tweet media one

0

10

40

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Heme boards- Iron resistant iron deficiency anemia (IRIDA) ⭐️Mutation:TMPRSS6 gene⬆️hepcidin synthesis➡️impairs Fe absorption ⭐️Q:IDA not responsive to oral Fe 🪧low iron&tsat 🪧low normal ferritin 🪧smear👇IDA ⭐️R/O:H.pylori/autoimmune gastritis,celiac disease ⭐️ttt:IV iron

Tweet media one

0

7

41

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

Going to #IMS2022 #mmsm @Myeloma_Society hope to see everybody there

Tweet media one

3

3

41

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

🧵Check out our analysis of BOSTON trial for the use of Selinexor in MM #mmsm with a great mentor @szusmani @ASH_hematology #Diffusion #TheHematologist 👇some highlights👇

Tweet media one

8

10

39

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

2 years

#ASH22 well this is a very long line on Taxi. Moreover no Uber available. @ASH_hematology traffic

Tweet media one

5

3

39

@HadidiSamer

Samer Al Hadidi, MD,MS,FACP

3 years

Oncology boards @ASCO Choosing Wisely #MedTwitter ⭐️Important & commonly asked questions⭐️ 10 recommendations, summarized below👇 ➡️Link:

Tweet media one

1

19

40